Adaptive Biotechnologies/$ADPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Ticker
$ADPT
Sector
Primary listing
Employees
624
Headquarters
Website
ADPT Metrics
BasicAdvanced
$2.2bn
-
-$0.32
2.16
-
Price and volume
Market cap
$2.2bn
Beta
2.16
52-week high
$20.76
52-week low
$8.50
Average daily volume
1.6m
Financial strength
Current ratio
3.354
Quick ratio
3.083
Long term debt to equity
86.453
Total debt to equity
92.838
Interest coverage (TTM)
-3.97%
Profitability
EBITDA (TTM)
-29.786
Gross margin (TTM)
43.71%
Net profit margin (TTM)
-16.82%
Operating margin (TTM)
-15.82%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-5.74%
Return on equity (TTM)
-23.95%
Valuation
Price to revenue (TTM)
7.203
Price to book
10.25
Price to tangible book (TTM)
23.07
Price to free cash flow (TTM)
-72.045
Free cash flow yield (TTM)
-1.39%
Free cash flow per share (TTM)
-0.193
Growth
Revenue change (TTM)
55.87%
Earnings per share change (TTM)
-66.20%
3-year revenue growth (CAGR)
17.02%
3-year earnings per share growth (CAGR)
-38.08%
What the Analysts think about ADPT
Analyst ratings (Buy, Hold, Sell) for Adaptive Biotechnologies stock.
ADPT Financial Performance
Revenues and expenses
ADPT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs